QUIGLEY ANNOUNCES PRECLINICAL RESULTS FOR QR440

Quigley has obtained the results from a series of in-vivo inflammation studies conducted at a leading university research center of a potential broad-spectrum anti-inflammatory, all natural, botanical compound (QR440).

QR440 was initially tested to determine its effect upon delayed-type- hypersensitivity (DTH). DTH is Th-1 type T cell response that initiates immune-mediated inflammation. It was found DTH responses were significantly reduced in QR440-treated mice at 24 hours post challenge.

A second study tested the compound's effect on granulocyte migration. An anaerobic bacterial growth medium was introduced into the mice to induce the mobilization of granulocytes. Compound QR440 significantly inhibited the recruitment of granulocytes into the site of inflammation.

These studies demonstrate that QR440 has a significant effect on both sterile and immune mediated inflammation without resorting to large doses, the company said.